Postprandial hyperglycemia—defined as blood glucose exceeding 11.1 mmol/L two hours after a meal—is a common and clinically significant challenge in type 2 diabetes mellitus (T2DM). It contributes not only to suboptimal glycemic control but also independently increases the risk of cardiovascular complications, making it a critical therapeutic target in routine diabetes management.
Several pharmacologic classes are currently used to address elevated postprandial glucose levels, including alpha-glucosidase inhibitors (e.g., acarbose), insulin secretagogues, exogenous insulin, and glucagon-like peptide-1 (GLP-1) receptor agonists. Among these, alpha-glucosidase inhibitors work by delaying intestinal carbohydrate digestion and absorption. While acarbose has demonstrated efficacy in reducing postprandial glucose excursions, its clinical utility is often limited by gastrointestinal side effects—including flatulence, abdominal discomfort, and diarrhea—as well as rare but notable risks of hepatic and renal toxicity with long-term use. These factors can compromise treatment adherence and tolerability, particularly among newly diagnosed patients or those consuming high-starch diets.
In response to these limitations, a novel botanical-derived therapy has emerged: mulberry twig total alkaloids (MTA) tablets—marketed as Sangbon®—the world’s first approved antihyperglycemic drug derived from purified active components of a plant source. Its principal bioactive constituents—alkaloids isolated and purified from the twigs of *Morus alba* L.—exhibit potent and highly selective inhibition of alpha-glucosidase enzymes. This mechanism specifically impedes the breakdown of dietary oligosaccharides and disaccharides into absorbable glucose, thereby blunting postprandial glycemic spikes with greater precision than conventional agents.
A randomized controlled trial comparing MTA with acarbose in patients with T2DM presenting the traditional Chinese medicine pattern of “phlegm-dampness and blood stasis” found equivalent reductions in postprandial glucose levels between the two treatments. However, MTA demonstrated superior outcomes across multiple domains: greater improvement in TCM syndrome scores, enhanced overall clinical efficacy, more pronounced reductions in total cholesterol and inflammatory biomarkers, and—critically—a significantly lower incidence of gastrointestinal adverse events, especially bloating and flatulence. Based on these findings, MTA is increasingly recommended as a first-line option for postprandial glucose management in individuals with starch-rich diets and in newly diagnosed T2DM patients.
Beyond its targeted effect on carbohydrate digestion, preclinical and emerging clinical evidence suggests that MTA exerts pleiotropic metabolic benefits. These include stimulation of endogenous GLP-1 secretion, protection of pancreatic beta-cell function, attenuation of insulin resistance, modulation of gut microbiota composition, improvement of lipid metabolism, and modest weight stabilization. Collectively, these actions support not only glycemic control but also broader cardiometabolic health—addressing key drivers of long-term diabetic complications.
In summary, mulberry twig total alkaloids represent a scientifically validated, plant-based therapeutic advance for postprandial hyperglycemia in T2DM. With robust glucose-lowering efficacy, an improved safety and tolerability profile compared with acarbose, and multifaceted metabolic advantages, MTA offers a compelling option for clinicians seeking individualized, patient-centered approaches to early and sustained glycemic management. As with all antidiabetic therapies, treatment decisions should be guided by comprehensive assessment, shared decision-making, and strict adherence to prescribing information—patients must never adjust dosing or discontinue therapy without medical supervision.